TEAM

  • Highly qualified personnel
  • 32 chemists in 2017
  • 40 chemists in 2018
  • Capability for up to 70!!!!

SPACE

  • Current lab around 600m2
  • MGRC lab is around 3000m2

CAPABILITIES

  • KiloLab: from 1L to 30L
  • Hydrogenation: from 100ml to 2ml, and up to 60Bar
  • Cryogenic reactions: from 100ml to 30ml, -70℃ to 185℃ 
  • HPAPIs: development and kilolab facility (in 2018)

SKILLS

  • Pragmatic Route Selction
  • Analytical & Process Development following Quality by Design strategies
  • Expertise in Control Strategy to support process registration and validation
  • Synthesis and characterization of impurities
  • High regulatory, technical and IP knowledge
  • Process Safety studies performed in-house
  • Controlled Substances Handling

MOEHS GROUP
RESEARCH CENTER

Since its foundation in 1962, MOEHS has been producing Active Ingredients, its corresponding intermediates and fine chemicals for the international Pharmaceutical Industry.


During more than 50 years, MOEHS has developed considerable technical expertise and experience.


Lately we have been working on our new facility on molecules suitable to be filed as a paragraph IV to be lunched in USA market.


Contact us for more information.

Go to article: Home | Invest in TechGo to article: In this issueGo to article: Gerteis Company InsightGo to article: GerteisGo to article: ContentsGo to article: DJAGo to article: NewsGo to article: MedelpharmGo to article: Biotech M&A: will the 2018 surge last?Go to article: NSFGo to article: Can the gene and cell therapy revolution scale up?Go to article: Haselmeier GmbH Company InsightGo to article: Haselmeier GmbH Go to article: Gut instinct: how common drugs affect the microbiomeGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Tracing the story of mumps: a timelineGo to article: Molnar Company InsightGo to article: MolnarGo to article: Inside Swiss pharma: the ideal environment for successGo to article: Is the UK’s drug evaluation system in need of an overhaul?Go to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: MoehsGo to article: Could digital tech unlock billions in savings for pharma companies?Go to article: EcocoolGo to article: CRISPR: a seismic shift in gene editingGo to article: Mestra AG (Endress + Hauser)Go to article: EventsGo to article: Pfanstiehl Inc Company InsightGo to article: Pfanstiehl Inc.Go to article: Next issueGo to article: Niconex Medical LtdGo to article: Alpex Pharma SAGo to article: Pall Biotech Company InsightGo to article: Pall BiotechGo to article: AtoZ-CRO GmbHGo to article: WIKA - Disaster preventionGo to article: Bea TechnologiesGo to article: BaxterGo to article: SuezGo to article: Raland Compliance Partners